FY26 is a potent Os(II) anticancer drug candidate, exerts its activity by generating reactive oxygen species and disrupting the redox balance in cancer cells Coadministration of FY26 and nontoxic doses of L-BSO allows the potentiation of its anticancer activity, and most remarkably, it improves the selectivity for cancer cells versus normal fibroblasts. FY26 is 49 times more potent than the clinically used treatment Cisplatin. FY26 is able to shut down a cancer cell by exploiting weaknesses inherent in their energy generation. References:

纯度：≥98%

CAS：1255143-82-8